Apimeds Pharmaceuticals US (APUS) Common Equity (2023 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported Common Equity for 4 consecutive years, with $106.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 993.16% year-over-year to $106.4 million; the trailing twelve-month figure through Jun 2026 stood at $106.4 million (up 993.16% YoY), and the FY2025 full-year result was $153.3 million, up 11391.18% from the prior year.
• Common Equity slipped to $106.4 million in Q2 2026 per APUS's latest filing, from $153.3 million in the prior quarter.
• Across five years, Common Equity topped out at $153.3 million in Q4 2025 and bottomed at -$1.8 million in Q1 2025.
• Historically, Common Equity has averaged $27.3 million across 4 years, with a median of -$116367.5 in 2023.
• The sharpest annual moves came in 2024 and 2025: Common Equity sank 4361.57% in 2024, then surged 11391.18% in 2025.
• Over 4 years, Common Equity stood at $31869.0 in 2023, then tumbled by 4361.57% to -$1.4 million in 2024, then soared by 11391.18% to $153.3 million in 2025, then sank by 30.58% to $106.4 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $106.4 million, $153.3 million, and $8.2 million for Q2 2026, Q4 2025, and Q3 2025 respectively.